Trade Pharming Group N.V. - PHAR CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.004 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.017263% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | -0.004959% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 10 | ||||||||
| Currency | EUR | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | Netherlands | ||||||||
| Commission on trade | 0% |
| Prev. Close | 0.72 |
| Open | 0.74 |
| 1-Year Change | -17.59% |
| Day's Range | 0.736 - 0.754 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 24, 2025 | 0.720 | -0.011 | -1.50% | 0.731 | 0.737 | 0.720 |
| Apr 23, 2025 | 0.746 | 0.037 | 5.22% | 0.709 | 0.752 | 0.707 |
| Apr 22, 2025 | 0.704 | 0.008 | 1.15% | 0.696 | 0.705 | 0.682 |
| Apr 17, 2025 | 0.701 | 0.004 | 0.57% | 0.697 | 0.704 | 0.692 |
| Apr 16, 2025 | 0.704 | -0.006 | -0.85% | 0.710 | 0.710 | 0.697 |
| Apr 15, 2025 | 0.709 | -0.001 | -0.14% | 0.710 | 0.718 | 0.704 |
| Apr 14, 2025 | 0.713 | 0.014 | 2.00% | 0.699 | 0.714 | 0.686 |
| Apr 11, 2025 | 0.682 | -0.018 | -2.57% | 0.700 | 0.700 | 0.676 |
| Apr 10, 2025 | 0.694 | -0.060 | -7.96% | 0.754 | 0.754 | 0.689 |
| Apr 9, 2025 | 0.702 | 0.002 | 0.29% | 0.700 | 0.722 | 0.693 |
| Apr 8, 2025 | 0.745 | 0.026 | 3.62% | 0.719 | 0.751 | 0.712 |
| Apr 7, 2025 | 0.699 | 0.020 | 2.95% | 0.679 | 0.719 | 0.649 |
| Apr 4, 2025 | 0.705 | -0.004 | -0.56% | 0.709 | 0.730 | 0.696 |
| Apr 3, 2025 | 0.717 | 0.008 | 1.13% | 0.709 | 0.738 | 0.709 |
| Apr 2, 2025 | 0.734 | 0.009 | 1.24% | 0.725 | 0.739 | 0.719 |
| Apr 1, 2025 | 0.746 | -0.018 | -2.36% | 0.764 | 0.779 | 0.739 |
| Mar 31, 2025 | 0.779 | -0.013 | -1.64% | 0.792 | 0.797 | 0.769 |
| Mar 28, 2025 | 0.796 | 0.010 | 1.27% | 0.786 | 0.810 | 0.782 |
| Mar 27, 2025 | 0.811 | 0.002 | 0.25% | 0.809 | 0.828 | 0.800 |
| Mar 26, 2025 | 0.811 | -0.001 | -0.12% | 0.812 | 0.818 | 0.807 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Pharming Group Company profile
About Pharming Group N.V.
Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Pharming Group N.V. revenues decreased 10% to EUR167.7M. Net income decreased 59% to EUR13.5M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net income also reflects Research and development increase of 76% to EUR59.3M (expense), General and administrative increase of 48% to EUR31.2M (expense).
Equity composition
4/2010, Nominal value changed from EUR 0.5. 07/2012, Nominal value changed from EUR0.04. 3/2013, 1-for-10 reverse stock split (Factor: 0.1 ). 3/2013, Nominal value changed from EUR0.1 to EUR0.01. 11/2016, Rights Issue, 1 new share for every 7 shares held @ 0.205EUR, (Factor: 1.00751).
| Industry: | Pharmaceuticals (NEC) |
Darwinweg 24
LEIDEN
ZUID-HOLLAND 2333 CR
NL
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com